Abstracts

Single-Dose PK/Safety of DTG-Dispersible Tablets in Neonates Supports Multi-Dosing: Petite-DTG Study

Background: Dolutegravir dispersible tablets (DTG-DT) are approved for infants ≥3 kg and aged >4 weeks but their suitability for neonates remains unknown. We evaluated the pharmacokinetics (PK) and safety of pediatric DTG-DT in neonates born to women on DTG-based therapy. Methods: PETITE-DTG is an ongoing phase I/II, open-label, single center, two-stage trial in South Africa…

Circulating HBV RNA Helps Characterize HBV Disease in Senegal

Background: Hepatitis B virus (HBV) infection affects >10% of the population in West Africa and is the most common cause of liver cirrhosis and hepatocellular carcinoma. Circulating HBV RNA may help improve the characterization of HBV disease and prognosis. We aimed to evaluate the associations between HBV RNA and conventional biomarkers of HBV replication in…

Re-Infection Following a Minimal Monitoring Approach for Treatment of Hepatitis C Virus Infection

Background: MINMON (ACTG A5360) trial demonstrated that a minimal monitoring approach for HCV treatment with sofosbuvir-velpatasvir (SOF/VEL) was safe and efficacious (sustained viral response [SVR]: 95%) in a diverse global population. In a phylogenetic analysis, we estimated HCV re-infection rates among participants with post-treatment HCV RNA >lower limit of quantification (LLoQ). Methods: HCV RNA evaluations…

Real-World Utilization of Cabotegravir + Rilpivirine in the US: Data From Trio Health Cohort

Background: Cabotegravir+Rilpirivine (CAB+RPV) is the first complete long-acting (LA) antiretroviral regimen approved in the United States for the treatment of HIV for ART-experienced people with undetectable viral load (VL 200 copies/mL or 1 VL > 200 copies/mL with discontinuation within 4 months of last recorded injection. ARV resistance from HIV genotype results was available for…

Elevated Plasma IL-10 and Type I Interferon Predict Faster HIV Reservoir Decay in Acute Treated HIV

Background: The HIV reservoir largely consists of ‘defective’ virus, but the elimination of the ‘intact’ (replication-competent) reservoir is a major focus of HIV eradication strategies. There are limited data describing reservoir decay rates during the first few months of acute-treated HIV, nor the host immune responses that drive reservoir decay. We quantified plasma cytokine levels…

Model-Based Comparison of Cabotegravir Pharmacokinetics Following Thigh and Gluteal Injections

Background: Cabotegravir (CAB) long-acting (LA) intramuscular (IM) gluteal injections are approved for HIV-1 pre-exposure prophylaxis (PrEP) and combination treatment with rilpivirine. The vastus lateralis (lateral) thigh muscle is a potential alternative site of administration in cases of gluteal injection fatigue or physical obstruction. We aimed to characterize CAB pharmacokinetics (PK) and its association with demographics…